|
|
 |
|
Viewing report
|
|
|
|
Shire plc Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Merchant Research and Consulting Ltd, April 2011, Pages: 89
Shire plc Fundamental Company Report is an absolutely essential resource for anyone looking for detailed information on the above-mentioned company. Using a wide range of primary and secondary sources, all available data about Shire plc has been combined, analyzed and presented in the all-in-one report. In addition to the descriptive part, the report provides a fundamental analysis which allows readers to compare Shire plc to its direct competitors and find out its position in the Pharmaceuticals and Biotechnology Industry, as well as detect the company’s strengths, weaknesses, opportunities and threats. The report also features opinions, estimates and next quarter/year forecasts by stock market experts and analysts.
Scope:
- The report contains Shire plc key data and company profile (key executives and owners, locations and subsidiaries, markets and products, company history, etc.).
- SWOT-analysis (company’s strengths, weaknesses, opportunities and threats) is provided.
- The report indicates financial ratios (profitability, margin analysis, asset turnover, credit ratios, long-term solvency), including ratio trend charts.
- Company’s income statement, balance sheet and cash flow are presented for the latest 4 years and latest 4 quarters, including trend charts.
- Financial ratios of Shire plc are compared with ratios of direct competitors and industry averages.
- We provide news and PR activity analysis, comparing stock price movements with essential news and press releases.
- Expert estimates include next quarter/year forecasts, which reveal change dynamics and contain opinions of other research firms.
Reasons to Buy
The immediate benefits of buying this report are as follows:
- Your knowledge of the investigated company will become unparalleled.
- Unique analysis of the market and competitors as well as detailed knowledge of both internal and external factors impacting the industry will take you one step further in managing your business environment.
- You will boost your company’s business/sales activities by getting an insight into your competitors’ businesses.
- Your search for prospective partners and suppliers will be largely facilitated.
- Indispensible annual profitability data will strengthen your decision-making process.
About Shire plc
Shire plc, a specialty biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of pharmaceutical products. The company focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies, and gastrointestinal (GI) diseases, as well as opportunities in other therapeutic areas.
Segments
The company operates in two segments: Specialty Pharmaceuticals and Human Genetic Therapies (HGT).
SPECIALTY PHARMACEUTICALS
Treatments for ADHD VYVANSE: VYVANSE is a new chemical entity for the treatment of ADHD and is the first pro-drug stimulant, where the amino acid l-lysine is linked to d-amphetamine, which is therapeutically inactive until metabolized in the body. VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 years was approved in 2007 and is available in the U.S. in six dosage strengths: 20mg, 30mg, 40mg, 50mg, 60mg and 70mg, all indicated for once-daily dosing. In April 2008 the FDA approved the adult indication for VYVANSE, making it the first and only once-daily pro-drug stimulant approved to treat adults aged over 18 years with ADHD. Shire launched VYVANSE in the U.S. for adults with ADHD in June 2008. In February 2009 Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 years in Canada. Shire launched VYVANSE in Canada in February 2010. In May 2009 Shire and GSK commenced working together on the co-promotion of VYVANSE for the treatment of ADHD in adults with the aim of improving recognition and treatment of adult ADHD in the U.S. INTUNIV: INTUNIV is a new class of approved ADHD medications, a selective alpha-2A receptor agonist indicated for the treatment of ADHD. The FDA approved INTUNIV in September 2009 as a once daily treatment for children and adolescents aged 6 ? 17 years. Shire launched INTUNIV in November 2009. EQUASYM: In March 2009, Shire acquired from UCB the worldwide rights (excluding the U.S., Canada, and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 ? 18 years. EQUASYM XL is commercially available in ten countries in 10mg, 20mg, and 30mg strengths. EQUASYM is marketed in Mexico and South Korea under the trade name METADATE CD. DAYTRANA: DAYTRANA is a methylphenidate transdermal delivery system for the once daily treatment of ADHD. It is available in four dosage strengths of 10mg, 15mg, 20mg, and 30mg, all designed for once-daily use. ADDERALL XR: ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once daily dosing. It is available in 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and can be administered either as a capsule or sprinkled on soft food. The FDA approved ADDERALL XR as a once-daily treatment for children aged 6 to 12, adults, and adolescents (aged 13 to 17). Treatments for GI diseases PENTASA: PENTASA controlled release capsules are indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the U.S. in 250mg and 500mg capsules. LIALDA/MEZAVANT: LIALDA is indicated for the induction of remission in patients with mild to moderately active ulcerative colitis. LIALDA is an approved once-daily oral formulation of mesalamine for induction of remission. Once-daily LIALDA contains the highest mesalamine dose per tablet (1.2g). In April 2008, TAP Pharmaceutical Products Inc. (TAP) commenced co-promotion of LIALDA in the U.S. Treatments for diseases in other therapeutic areas FOSRENOL: FOSRENOL is a phosphate binder that is indicated for use in end-stage renal failure patients receiving dialysis. FOSRENOL binds dietary phosphate in the gastrointestinal tract to prevent it from passing through the gut lining and, based upon this mechanism of action, phosphate absorption from the diet is decreased. Formulated as a chewable
|
|
|
|
